Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)

Summary

Evaluation of spironolactone, a well-known cardiological treatment, in patients with rheumatoid arthritis (RA). The hypothesis is that spironolactone, through its anti-inflammatory and anti-fibrosis actions, decreases RA's activity. The primary objective is to assess the efficacy of spironolactone on RA activity by evaluating the proportion of patients achieving DAS28-CRP \< 3.2 at 3 months (comparison between spironolactone and placebo arms). CRP (C reactive protein)

Timeline

Start

2022-06-22

Primary completion

2026-03

Completion

2026-03

Drugs

Indications